Drug-induced long QT and torsade de pointes: recent advances

Purpose of review A wide array of drugs can cause marked QT prolongation with the associated risk of torsade de pointes. The large number of drugs with this potential, the correspondingly large number of patients exposed to such drugs, and the potentially fatal outcome make drug-induced long QT syndrome an important public health problem. This review focuses on mechanisms underlying QT prolongation and proarrhythmia, risk factors, including the role of genetic variants, and the unifying framework of reduced repolarization reserve. Recent findings While most drugs that prolong the QT block a specific potassium channel, novel mechanisms altering protein trafficking have been discovered. The progression to torsade de pointes may be less related to degree of QT prolongation than to drug effects on transmural dispersion or variability of repolarization. Our understanding of certain predisposing risk factors has been further refined. Summary Ongoing research continues to elucidate the mechanisms underlying drug-induced long QT syndrome. Importantly, studies are establishing improved predictors of risk for progression to torsade de pointes, in addition to the degree of QT prolongation, which is an imperfect predictor. Nonetheless, drug-induced long QT syndrome and torsade de pointes pose unique challenges for clinicians, researchers, drug-development programs, and regulatory agencies.

[1]  D. Roden,et al.  Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome. , 2008, Journal of the American College of Cardiology.

[2]  D. Roden,et al.  P1-22: Persistent atrial fibrillation is associated with reduced risk of Torsades de Pointes in patients with drug-induced long QT syndrome , 2006 .

[3]  Hua-rong Lu,et al.  Calmodulin Antagonist W‐7 Prevents Sparfloxacin‐Induced Early Afterdepolarizations (EADs) in Isolated Rabbit Purkinje Fibers: Importance of Beat‐to‐Beat Instability of the Repolarization , 2006, Journal of cardiovascular electrophysiology.

[4]  M. Sanguinetti,et al.  hERG potassium channels and cardiac arrhythmia , 2006, Nature.

[5]  C. January,et al.  Most LQT2 Mutations Reduce Kv11.1 (hERG) Current by a Class 2 (Trafficking-Deficient) Mechanism , 2006, Circulation.

[6]  P. Schwartz.  The congenital long QT syndromes from genotype to phenotype: clinical implications , 2006, Journal of internal medicine.

[7]  D. Roden.  Long QT syndrome: reduced repolarization reserve and the genetic link , 2006, Journal of internal medicine.

[8]  P. C. Viswanathan,et al.  New Mechanism Contributing to Drug-Induced Arrhythmia: Rescue of a Misprocessed LQT3 Mutant , 2005, Circulation.

[9]  Charles Antzelevitch,et al.  Role of transmural dispersion of repolarization in the genesis of drug-induced torsades de pointes. , 2005, Heart rhythm.

[10]  J. Turgeon,et al.  Drug-induced long QT syndrome and torsade de pointes. , 2005, The Canadian journal of cardiology.

[11]  P. C. Viswanathan,et al.  Genetics of acquired long QT syndrome. , 2005, The Journal of clinical investigation.

[12]  Jun Zhou,et al.  Pentamidine reduces hERG expression to prolong the QT interval , 2005, British journal of pharmacology.

[13]  G. Salama,et al.  Sex Modulates the Arrhythmogenic Substrate in Prepubertal Rabbit Hearts with Long QT 2 , 2005, Journal of cardiovascular electrophysiology.

[14]  A. Arya.  Gender‐Related Differences in Ventricular Repolarization: Beyond Gonadal Steroids , 2005, Journal of cardiovascular electrophysiology.

[15]  M. Holm,et al.  In vivo validation of the coincidence of the peak and end of the T wave with full repolarization of the epicardium and endocardium in swine. , 2005, Heart rhythm.

[16]  D. Roden,et al.  Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives. , 2005, Heart rhythm.

[17]  K. Sunagawa,et al.  Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil. , 2005, Journal of the American College of Cardiology.

[18]  Y. Kuryshev,et al.  Pentamidine-Induced Long QT Syndrome and Block of hERG Trafficking , 2005, Journal of Pharmacology and Experimental Therapeutics.

[19]  M. Grabowski,et al.  Drug-Induced Long-QT Syndrome With Macroscopic T-Wave Alternans , 2004 .

[20]  Milan Stengl,et al.  Increased Short-Term Variability of Repolarization Predicts d-Sotalol–Induced Torsades de Pointes in Dogs , 2004, Circulation.

[21]  K. Murray,et al.  Relationship between area deprivation and the anticaries benefit of an oral health programme providing free fluoride toothpaste to young children. , 2004, Community dentistry and oral epidemiology.

[22]  S. Chism,et al.  Drug-induced long QT syndrome and Torsade de Pointes. , 2004, The Journal of the Arkansas Medical Society.

[23]  Gregory W. Kauffman,et al.  Physicochemical Features of the hERG Channel Drug Binding Site* , 2004, Journal of Biological Chemistry.

[24]  H. Mabuchi,et al.  T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity. , 2003, Clinical science.

[25]  J. Mason,et al.  A new oral therapy for long QT syndrome: long-term oral potassium improves repolarization in patients with HERG mutations. , 2003, Journal of the American College of Cardiology.

[26]  Li Zhang,et al.  Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. , 2003, Journal of the American College of Cardiology.

[27]  C. January,et al.  Pharmacological Rescue of Human K+ Channel Long-QT2 Mutations: Human Ether-a-Go-Go-Related Gene Rescue Without Block , 2002, Circulation.

[28]  P. C. Viswanathan,et al.  Allelic Variants in Long-QT Disease Genes in Patients With Drug-Associated Torsades de Pointes , 2002, Circulation.

[29]  Jeffrey R. Balser,et al.  A sensitive mechanism for cation modulation of potassium current , 2000, Nature Neuroscience.

[30]  D. Roden,et al.  Exaggerated QT prolongation after cardioversion of atrial fibrillation. , 1999, Journal of the American College of Cardiology.

[31]  C. January,et al.  Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. , 1999, Circulation research.

[32]  C. Antzelevitch,et al.  Cellular and ionic basis for T-wave alternans under long-QT conditions. , 1999, Circulation.

[33]  D. Roden,et al.  Normalization of acquired QT prolongation in humans by intravenous potassium. , 1997, Circulation.

[34]  D M Roden,et al.  Rapid inactivation determines the rectification and [K+]o dependence of the rapid component of the delayed rectifier K+ current in cardiac cells. , 1997, Circulation research.

[35]  D. Roden,et al.  Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. , 1996, Circulation.

[36]  K Shimomura,et al.  Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. , 1995, Journal of the American College of Cardiology.

[37]  E. Green,et al.  A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome , 1995, Cell.

[38]  M. Lehmann,et al.  Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs , 1993 .

[39]  M. Lehmann,et al.  Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. , 1993, JAMA.

[40]  R. Prineas,et al.  Sex differences in the evolution of the electrocardiographic QT interval with age. , 1992, The Canadian journal of cardiology.

[41]  R. Woosley,et al.  Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin , 1992, Clinical pharmacology and therapeutics.

[42]  R. Lazzara.  Amiodarone and torsade de pointes. , 1989, Annals of internal medicine.

[43]  D. Roden,et al.  Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. , 1986, American heart journal.

[44]  G. Kay,et al.  Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. , 1983, Journal of the American College of Cardiology.